The clinical investigation included nine patients, seven of whom had progressed to the disease stage during intervention with brentuximab, and reported that CD30 CAR-Ts treatment is safe and can lead to favorable clinical responses in patients with HL [128]. Here, TNFRSF8 is linked to Hodgkins lymphoma.